Copyright
©The Author(s) 2025.
World J Clin Oncol. Jun 24, 2025; 16(6): 108393
Published online Jun 24, 2025. doi: 10.5306/wjco.v16.i6.108393
Published online Jun 24, 2025. doi: 10.5306/wjco.v16.i6.108393
Table 3 Annual percent change of ovarian carcinoma-related age-adjusted mortality rates per 100000 in females in the United States, 1999 to 2020
Year interval | APC (95%CI) |
Overall | |
1999-2003 | 0.41 (-0.48 to 1.79) |
2003-2020 | -2.28a (-2.39 to -2.16) |
NH White | |
1999-2002 | 0.66 (-0.49 to 2.36) |
2002-2006 | -1.34a (-2.67 to -0.60) |
2006-2020 | -2.4034a (-3.30 to -1.95) |
NH Black or African American | |
1999-2002 | 1.16 (-1.48 to 6.05) |
2002-2020 | -1.71a (-3.26 to -1.46) |
NH American Indian or Alaska Native | |
1999-2020 | -1.00 (-2.18 to 0.42) |
Hispanic or Latino | |
1999-2005 | 0.30 (-1.10 to 5.47) |
2005-2020 | -1.72a (-2.77 to -1.41) |
NH Asian or Pacific Islander | |
1999-2020 | -0.85a (-1.16 to -0.46) |
Young aged (25-44 years) | |
1999-2020 | -1.83a (-2.20 to -1.46) |
Middle aged (45-64 years) | |
1999-2020 | -2.17a (-2.41 to -1.92) |
Old aged (65 to > 85 years) | |
1999-2001 | 2.31 (-0.09 to 4.28) |
2001-2007 | -0.90a (-2.80 to -0.45) |
2007-2020 | -2.88a (-3.12 to -2.67) |
Non-metropolitan areas | |
1999-2004 | 0.50 (-0.56 to 2.55) |
2004-2020 | -2.20a (-2.47 to -1.98) |
Metropolitan areas | |
1999-2003 | 0.27 (-0.69 to 1.79) |
2003-2020 | -2.31a (-2.45 to -2.19) |
Northeast region | |
1999-2002 | 1.15 (-0.84 to 4.52) |
2002-2020 | -2.39a (-2.60 to -2.22) |
Midwest region | |
1999-2003 | 0.62 (-0.85 to 3.62) |
2003-2020 | -2.37a (-2.64 to -2.17) |
South region | |
1999-2005 | -0.37 (-1.02 to 0.81) |
2005-2020 | -2.29a (-2.50 to -2.11) |
West region | |
1999-2004 | 0.12 (-0.51 to 1.09) |
2004-2008 | -3.18a (-4.24 to -2.32) |
2008-2016 | -1.64a (-1.93 to -0.29) |
2016-2020 | -3.58a (-5.02 to -2.76) |
- Citation: Razaq L, Dhali A, Maity R, Faisal AR, Hafeez AS, Zaman A, Humayun MA, Faizan M, Shahid M, Majeed M, Singh P. Demographic trends in mortality due to ovarian cancer in the United States, 1999-2020. World J Clin Oncol 2025; 16(6): 108393
- URL: https://www.wjgnet.com/2218-4333/full/v16/i6/108393.htm
- DOI: https://dx.doi.org/10.5306/wjco.v16.i6.108393